Harvest CSI Hong Kong Connect Innovative Drugs ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

512010

589720

159286

517380

520970

159835

159316

159858

516060

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

ChinaAMC CSI Biotechnology Theme ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Yinhua CSI Innovative Drugs Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

GF CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern CSI Brand Name Drug Industry ETF

ICBCCS CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

600547

GDXW

588700

513120

Last week (from March 30 to April 3), the Shanghai Composite Index slightly fell by 0.86%, while the growth style index was significantly adjusted downwards. The pharmaceutical commerce and precious metals sectors performed strongly, with the innovative drug ETF leading the gains, and the ICBC Innovative Drug ETF rising by 6.9%. Despite a net outflow of 4.042 billion yuan in the overall ETF market and an outflow of 12.117 billion yuan in equity ETFs, bond, commodity, and currency ETFs all achieved net inflows. The Hong Kong innovative drug market has stabilized, with low valuations and ample room for allocation, and the industry's fundamentals have improved, indicating that the subsequent market trend is expected to fluctuate upwards

腾讯新闻 - 财经

SD-GOLD

Roundhill Gold Miners Weeklypay ETF

Harvest SSE STAR Biology and Medicine ETF

ZHONGJIN GOLD

GF CSI HK Innovative Drugs Industry ETF(QDII)

EFUND GOLD MI ETF

Pro Ultr GLD

SPDR GOLD TRT

Microsectors Gold Miners 3x Leveraged ETN

iShares MSCI Global Gold Miners

Yinhua CNI HK Connect Innovative Drugs ETF

Direxion Daily Jr Gold Miners Bull 2X

GLOBAL X Gold Explorers

ChinaAMC Gold ETF

Direxion Daily Gold Miners Bull 2X

VanEck Gold Miners ETF

SPDR Gold Minishares

Sprott GLD Miners Etf

EFUND GOLD MI-U

Us Gbl GLD & Met

EFUND GOLD MI-R

YieldMax Gold Miners Opt Inc Strgy ETF

Sprott JR Gold Miners ETF

Zijin Mining

Abrdn Gold ETF Trust

ICBCCS CNI HK Connect Innovative Drugs ETF

ETF Weekly Review: Innovative Drugs Dominate the Rankings, Gold Strongly Attracts Capital

161122

520700

513780

The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts

E Fund CSI WD Biotechnology Index Fund(LOF)-A

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

02157

The overseas licensing cooperation of innovative pharmaceutical companies continues to be active, and the Harvest CSI Hong Kong Connect Innovative Drugs ETF (520970) is expected to benefit continuously. On the morning of April 1, 2026, the CSI Hong Kong Connect Innovative Drugs Index rose by 4.91%, with constituent stock LEPU BIO-B increasing by 11.24%. In the first three months of 2026, the total value of foreign licensing transactions for innovative drugs in China has exceeded USD 60 billion. The NMPA has launched the "Spring Rain Action" for the transformation of clinical innovation achievements in medical devices, supporting the industrialization of innovative results. The valuation of the pharmaceutical sector is 29.3 times PE, lower than the historical average, and the market's attention to innovative pharmaceutical companies with core technology platforms has increased

LEPU BIO

Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting

520880

On March 27th, the Hong Kong Stock Connect Innovative Drug Index rose by 5.07%. CSPC Pharma increased by over 12%, 3SBIO rose by over 9%, and INNOVENT BIO climbed by over 7%. The Hong Kong Stock Connect Innovative Drug ETF, Harvest (520970), had a trading volume of 126 million yuan and a turnover rate of 12.26%. Several Hong Kong Stock Connect innovative drug targets disclosed their 2025 financial reports, with Hengrui Pharma's innovative drug revenue growing by 26% year-on-year. Zhongyou Securities is optimistic about investment opportunities in the sector, while Morgan Stanley believes that the internationalization of China's innovative drugs is accelerating and is currently in a left-side allocation window

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

INNOVENT BIO

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

CSPC PHARMA

China Southern CNI HK Connect Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

3SBIO

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

The internationalization of Chinese innovative drugs is accelerating, and the sector is in a left-side allocation window. The Hong Kong Stock Connect Innovative Drug ETF Harvest (520970) is gaining popularity

588860

159849

03069

As of March 24, the pharmaceutical sector has risen against the trend, with several companies such as KEYMED BIO-B and INSILICO showing significant gains. The industry is overall driven by dual engines of CXO pharmaceutical outsourcing services and ADC antibody-drug conjugates, with leading companies maintaining high performance and a stable policy environment. WuXi AppTec expects double-digit revenue growth by 2025, with ADC innovative drugs gradually entering the harvest period, increasing industry concentration, and deepening the competitive moat of leading enterprises. Investors may focus on ETFs in the biotechnology and innovative drug sectors

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

CAM HSBIOTECH

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Penghua CSI HK Connect Health Care Composite ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

KEYMED BIO-B

iShares Biotechnology ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

WuXi AppTec

EFUND BIOPHAR ETF

Ping An CSI Medicine and Medical Device Innovation ETF

GX CN BIOTECH

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

INSILICO

Direxion S&P Biotech Bull 3X

Minsheng Royal CSI Biotechnology Theme ETF

WUXI APPTEC

CAM HSBIOTECH-R

Hwabao WP CSI Pharmaceuticals ETF

WUXI BIO

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

WuXi Biologics

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

SPDR S&P Biotech

Guotai CSI Bio-medicine ETF

iShares US Pharma

The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector